Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$14 Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$-- Mln
ROE
-1.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.7
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
22,594,000
CFO
€-262.26 Mln
EBITDA
€-256.13 Mln
Net Profit
€-288.92 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Celyad Oncology SA - ADR
| 6.3 | 18.2 | -16.8 | -71.0 | -63.2 | -55.4 | -- |
|
BSE Sensex*
| -14.5 | -10.9 | -15.0 | -4.7 | 7.1 | 7.7 | 11.1 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Celyad Oncology SA - ADR
| -86.5 | -53.1 | -25.1 | -42.6 | -57.7 | 142.7 | -67.5 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Celyad Oncology SA - ADR
|
0.5 | 14.2 | 0.0 | -40.9 | -- | -170.7 | -- | 0.7 |
| 743.1 | 43,711.5 | 4,164.2 | 1,296.0 | 9.5 | 20.2 | 36 | 5.6 | |
| 20.5 | 1,088.5 | 0.5 | -147.4 | -29,734.7 | -150.3 | -- | 6.4 | |
| 22.3 | 12,800.6 | 19,628.0 | 978.0 | 9.1 | 6.8 | 11.4 | 0.8 | |
| 29.8 | 1,904.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.2 | 0.5 | |
| 6.0 | 244.4 | 67.0 | 1.5 | 37.3 | 2.2 | -- | 4.9 | |
| 1.4 | 121.0 | 2.7 | -47.2 | -86.4 | 734.6 | -- | 20.1 | |
| 5.4 | 557.3 | 9.2 | -184.2 | -518.6 | 265.7 | -- | 2.1 | |
| 34.1 | 1,482.3 | -11.6 | -68.1 | -- | 201.7 | -- | 65.0 | |
| 6.3 | 913.1 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 7.4 |
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic... CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. Read more
Co-Founder, CFO, Interim CEO & Director
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME
Co-Founder, CFO, Interim CEO & Director
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME
Headquarters
Mont-Saint-Guibert
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Celyad Oncology SA - ADR is $0.52 (NASDAQ) as of 20-Jul-2023 09:30 EDT. Celyad Oncology SA - ADR has given a return of -63.22% in the last 3 years.
Since, TTM earnings of Celyad Oncology SA - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Celyad Oncology SA - ADR are Rs -- and Rs -- as of 02-Apr-2026.
Celyad Oncology SA - ADR has a market capitalisation of $ 14 Mln as on 20-Jul-2023. As per SEBI classification, it is a company.
Before investing in Celyad Oncology SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.